Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Incarceration and Risk of HIV and HCV in PWID
Lancet Infect Dis; ePub 2018 Oct 29; Stone, et al
Incarceration is associated with substantial short-term increases in HIV and hepatitis C virus (HCV) acquisition risk among people who inject drugs (PWID) and may be a significant driver of HCV and HIV transmission among PWID. This according to a systematic review and meta-analysis that aimed to assess whether incarceration history elevates HIV or HCV acquisition among PWID. Published results from 20 studies and unpublished results from 21 studies were included. Researchers found:
- Recent incarceration was associated with an 81% (relative risk [RR] 1.81) increase in HIV acquisition risk and a 62% (RR 1.62) increase in HCV acquisition risk, with moderate heterogeneity between studies.
- Past incarceration was associated with a 25% increase in HIV (RR 1.25) and a 21% increase in HCV (RR 1.21).
- Novel interventions to minimize the risk of HCV and HIV acquisition are needed in this vulnerable population.
Stone J, Fraser H, Lim AG, et al. Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: A systematic review and meta-analysis. [Published online ahead of print October 29, 2018]. Lancet Infect Dis. doi:10.1016/ S1473-3099(18)30469-9.
This Week's Must Reads
Must Reads in Hepatitis
Glecaprevir/Pibrentasvir Efficacy & Safety Assessed, J Hepatol; ePub 2018 Nov 23; D’Ambrosio, et al
HCV Infection Among Children & Young Persons, J Hepatol; ePub 2018 Nov 26; Modin, et al
HCV Patients with Limited Access to Antiviral Therapy, Dig Liver Dis; ePub 2018 Nov 29; Lens, et al
Progression in the Elimination of HCV Infection, PLoS One; ePub 2018 Dec 4; Juanbeltz, et al
Increased HCV Screening in Veteran Populations, Jt Comm J Qual Patient Saf; ePub 2018 Sep 25; Wray, et al